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found a large variation in bone and cartilage parameters among 
individual subjects in each group, however, group-specific means 
demonstrate decreasing trends (in bone and cartilage parame- 
ters) in osteoarthritic subjects (especially in mild OA subjects). A 
positive relationship was established between cartilage changes 
and localized bone changes closest to the joint line, while a nega- 
tive relationship was established between cartilage changes and 
global bone changes farthest from the joint line. 
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NSAIDs and COXIBs: BENEFIT TO RISK EVALUATION 
Leslie J Crofford 
NSAIDs have long been a mainstay of treatment for patients 
with arthritis, leading to reduced pain and improved function and 
quality of life. The discovery of the cyclooxygenase-2 (COX-2) 
enzyme and pre-clinical data suggesting the potential for re- 
duced gastrointestinal toxicity associated with selective inhibition 
of COX-2 occurred concomitantly with increasing awareness of 
gastrointestinal (GI) toxicity produced by conventional, nonselec- 
tive nonsteroidal anti-inflammatory drugs (NSAIDs). Drugs that 
specifically inhibit COX-2 were developed and early testing sug- 
gested that improved GI safety was possible. However reassur- 
ing the endoscopy trial results, the medical community still de- 
manded proof that these drugs were different from the nons- 
elective NSAIDs. In 1998, the US Food and Drug Administra- 
tion (FDA) requested large clinical safety trials to support pos- 
sible modification of the standard GI warning on NSAIDs. These 
studies included the Vioxx Gastrointestinal Outcome Research 
(VIGOR) trial and the Celecoxib Long-term Arthritis Safety Study 
(CLASS). Although these trials were designed primarily to evalu- 
ate GI endpoints, overall safety data were accumulated that ulti- 
mately served to redirect the clinical discussion toward CV risk. 
Most recently with the withdrawal of rofecoxib and valdecoxib 
from the market in the US and changes in the labeling of non- 
selective drugs, the discussion regarding NSAIDs and COXlBs 
has focused almost exclusively on cardiovascular safety to the ex- 
clusion of possible GI safety and, more importantly, clinical benefit 
to patients with arthritis. Future discussion of this group of drugs 
must focus on a more comprehensive assessment of benefit and 
risk to all organ systems. 
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UPDATE ON NSAIDS: ARE THERE ALTERNATIVES? ARE 
THERE ALTERNATIVES TO NSAIDS/COXIBS? 
Sharon L Kolasinski 
Physicians and patients have growing concerns about the safety 
of nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxy- 
genase 2 inhibitors (coxibs). The first choice for treatment of 
osteoarthritis (OA) pain is considerably less obvious than just 
a short time ago. The controversies surrounding the use of 
NSAIDs/coxibs do, however, provide us with the opportunity 
to review and rethink our management strategies and to con- 
sider the risks and benefits associated with therapies other than 
NSAI Ds/coxibs. 
Guidance in OA treatment is available from a number of sources 
including the American College of Rheumatology Recommenda- 
tions for the Medical Management of Osteoarthritis of the Hip 
and Knee 2000 Update (Arthritis & Rheumatism 2000;43:1905- 
15) and the reports of the Standing Committee for International 
Clinical Studies Including Therapeutics of the European League 
Against Rheumatism for hip (Ann Rheum Dis 2005;64:669-81) 
and knee (Ann Rheum Dis 2003;62:1145-55) osteoarthritis. Both 
sets of guidelines were developed from a review of evidence from 
the literature, as well as the consensus of experts in the field. Both 
groups emphasize that optimal management requires individual 
assessment of the patient (comorbidities, level of pain, degree of 
disability, extent of structural damage) and the use of nonphar- 
macological therapies (education, exercise, weight reduction, as- 
sistive devices). Topical agents, intraarticular steroid or hyaluronic 
acid injections and surgical procedures including total joint arthro- 
plasty are among recommended options. However, practitioners 
and patients often still depend on oral analgesics as an essential 
component of comprehensive management. 
